  ABSTRACT
The American College of Cardiology and American Heart Association updated their joint guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery in 2007. The guidelines recommend preoperative cardiac testing only when the results may infl uence patient management. They specify four high-risk conditions for which evaluation and preoperative treatment are needed: unstable coronary syndromes, decompensated heart failure, signifi cant cardiac arrhythmias, and severe valvular disease. Patient-specifi c factors and the risk of the surgery itself are considerations in the need for an evaluation and the treatment strategy before noncardiac surgery. In most instances, coronary revascularization before noncardiac surgery has not been shown to reduce morbidity and mortality, except in patients with left main disease. The timing of surgery following percutaneous coronary intervention (PCI) depends on whether a stent was used, the type of stent, and the antiplatelet regimen.
  KEY POINTS
In addition to patient-specifi c factors, preoperative cardiac assessment should account for the risk of cardiac morbidity related to the procedure itself. Vascular surgery confers the highest risk, with reported rates of cardiac morbidity often greater than 5%.
Continuation of chronic beta-blocker therapy is prudent during the perioperative period.
Coronary revascularization prior to noncardiac surgery is generally indicated only in unstable patients and in patients with left main disease.
Nonurgent noncardiac surgery should be delayed for at least 30 days after PCI using a bare-metal stent and for at least 365 days after PCI using a drug-eluting stent.
Discontinuing antiplatelet therapy in patients with coronary stents may induce a hypercoagulable state within approximately 7 to 10 days.
I
n patients undergoing noncardiac surgery, preoperative intervention for a cardiac condition is rarely needed simply to reduce the risk of the surgery unless such intervention is indicated separate from the preoperative context. This is the overriding message of the 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery issued by the American College of Cardiology (ACC) and American Heart Association (AHA), 1 These syndromes should be the fi rst and most important consideration. Unstable angina is a hypercoagulable state, as is recent MI. The hypercoagulability of these conditions is compounded by the hypercoagulability induced by the perioperative setting itself. As a result, the rate of perioperative MI or death in the setting of unstable angina is as high as 28%. 2 In the case of unstable coronary syndromes, delaying surgery is appropriate if the risks of the surgery are deemed greater than its potential benefi ts.
• Decompensated heart failure, defi ned as New York Heart Association functional class IV disease or worsening or new-onset heart failure.
• Signifi cant arrhythmias, defi ned as high-grade or Mobitz II atrioventricular block, third-degree atrioventricular heart block, symptomatic ventricular arrhythmias, supraventricular arrhythmias with uncontrolled ventricular rate, symptomatic bradycardia, and newly recognized ventricular tachycardia.
• Severe valvular disease, defi ned as severe aortic stenosis and symptomatic mitral stenosis.
   CARDIAC RISK STRATIFICATION:
INITIAL PATIENT ASSESSMENT
Clinical risk factors and functional capacity
The Revised Cardiac Risk Index of Lee et al 3 remains the general paradigm for stratifying cardiac risk before noncardiac surgery. This validated index consists of six independent predictors of cardiac complications:
• High-risk surgery (intraperitoneal, intrathoracic, or suprainguinal vascular procedures) • Ischemic heart disease • History of congestive heart failure • History of cerebrovascular disease • Insulin therapy for diabetes mellitus • Preoperative creatinine level greater than 2.0 mg/dL. The more predictors a patient has, the greater the risk of perioperative complications. Thus, the Revised Cardiac Risk Index is a good tool for establishing a baseline risk level for use in determining whether a preoperative or perioperative intervention is likely to make a difference in the patient's surgical outcome. For the purpose of the algorithmic approach to testing, the surgical procedure is not considered a risk factor. Additionally, type 2 diabetes mellitus is also considered a risk factor.
Another important determinant of risk is the patient's functional capacity. A study of 600 patients undergoing major noncardiac procedures found that poor selfreported exercise capacity, defi ned as an inability to walk four blocks or climb two fl ights of stairs, was associated with signifi cantly more perioperative complications than was good exercise capacity. 4 Simple instruments such as the Duke Activity Status Index 5 can be used to estimate the patient's functional capacity.
Procedure-specifi c risk
In addition to patient-specifi c factors, surgery-specifi c cardiac risk can be important, especially in patients with more than two clinical risk factors. The ACC/AHA 2007 perioperative guidelines identify three categories of surgery-specifi c risk 1 : • Vascular surgery (the highest-risk category and also the most extensively studied), which has been associated with cardiac morbidity rates of greater than 5% in many reports. Examples include aortic and other major vascular surgery, as well as peripheral vascular surgery.
• Intermediate-risk surgery, for which reported cardiac morbidity rates range from 1% to 5%. Examples include intraperitoneal and intrathoracic procedures, carotid endarterectomy, head and neck surgery, orthopedic surgery, and prostate surgery.
• Low-risk surgery, for which reported cardiac morbidity rates are generally below 1%. Examples include endoscopic and superfi cial procedures, cataract surgery, breast surgery, and ambulatory surgery. Patients undergoing these procedures do not generally require * The ACC/AHA 2007 perioperative guidelines make recommendations by classifying the magnitude of benefi t versus risk (I = the intervention should be undertaken; IIa = the intervention is reasonable to undertake; IIb = the intervention may be considered; III = the intervention should not be undertaken) and assigning a level of supporting evidence (A = highest level of evidence; B = limited evidence; C = very limited evidence).
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Risk stratifi cation promotes good perioperative outcomes
Appropriate risk stratifi cation can make the day of surgery among the safest times for patients undergoing outpatient procedures. A retrospective analysis of Medicare claims from the late 1990s for more than 500,000 elderly patients undergoing low-risk procedures in various outpatient settings found that the mortality rate was only 1 in 50,000 on the day of surgery but increased substantially over the following 7 days and 30 days. 6 This was likely a refl ection of the diligence applied to managing patient-specifi c risk factors before proceeding to outpatient surgery.
  HEART RATE CONTROL Chronic beta-blockade can obviate need for cardiac testing
The DECREASE (Dutch Echocardiographic Cardiac Risk Evaluation Applying Strees Echo) II trial assessed the value of cardiac testing before major vascular surgery in intermediate-risk patients (ie, with one or two cardiac risk factors) receiving chronic beta-blocker therapy begun 7 to 30 days prior to surgery. 7 Among the study's 770 intermediate-risk patients, the primary outcomecardiac death or MI at 30 days-was no different between those randomized to receive stress testing or no stress testing. The investigators concluded that cardiac testing can safely be omitted in intermediate-risk patients if beta-blockers are used with the aim of tight heart rate control.
Continue ongoing beta-blocker therapy, start in select high-risk patients
The ACC/AHA 2007 perioperative guidelines recommend continuing beta-blocker therapy in patients who are already receiving these agents (Class I, Level C). For patients not already taking beta-blockers, their initiation is recommended in those undergoing vascular surgery who have ischemia on preoperative testing (Class I, Level B). The guidelines designate beta-blockers as "probably" recommended (Class IIa, Level B) for several other patient subgroups with high cardiac risk, mainly in the setting of vascular surgery. 1 Notably, the guidelines were written before publication of the Perioperative Ischemic Evaluation (POISE), 8 which questioned the risk/benefi t profi le of perioperative beta-blockade in patients with or at high risk of athero sclerotic disease (see the Poldermans-Devereaux debate on page S84 of this supplement), and therefore may require revision (an update is scheduled for release in November 2009).
  LIMITED ROLE FOR CORONARY REVASCULARIZATION
Until recently, no randomized trials had assessed the benefi t of prophylactic coronary revascularization to reduce the perioperative risk of noncardiac surgery. The fi rst large such trial was the Coronary Artery Revascularization Prophylaxis (CARP) study, which randomized 510 patients scheduled for major elective vascular surgery to undergo or not undergo coronary artery revascularization before the procedure. 9 The study found that revascularization failed to affect any outcome measure, including mortality or the development of MI, out to 6 years of follow-up. Notably, the CARP population consisted mostly of patients with single-, double-, or mild triple-vessel coronary artery disease, so the study was limited in that it did not include patients with strong indications for coronary artery bypass graft surgery (CABG). 7 A reanalysis of the CARP results by the type of revascularization procedure-CABG or percutaneous coronary intervention (PCI)-revealed that patients undergoing CABG had lower rates of death, MI, and additional revascularization procedures compared with those undergoing PCI, despite the presumably more extensive disease of the CABG recipients.
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Benefi t apparently limited to left main disease
Further analysis of patients in the CARP trial who underwent coronary angiography found that one subgroup-patients with left main disease-did experience an improvement in survival with preoperative coronary revascularization.
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In a subsequent randomized pilot study, Poldermans et al found no advantage to preoperative coronary revascularization among patients with extensive ischemia who underwent major vascular surgery. 12 While this study was not adequately sized to defi nitively address the value of preoperative revascularization in these high-risk patients, its results are consistent with those of the CARP trial.
In a retrospective cohort study of patients who underwent noncardiac surgery, Posner and colleagues found that rates of adverse cardiac outcomes among patients who had recent PCI (р 90 days before surgery) were similar to rates among matched controls with nonrevascularized coronary disease. 13 Patients who had had remote PCI (> 90 days before surgery) had a lower risk of poor outcomes than did matched controls with nonrevascularized disease, but had a higher risk than did controls without coronary disease. 
PREOPERATIVE CARDIAC RISK STRATIFICATION
   PATIENTS WITH CORONARY STENTS:
STENT TYPE AND TIME SINCE PLACEMENT ARE KEY The lack of benefi t from prophylactic PCI prior to noncardiac surgery also applies to PCI procedures that involve coronary stent placement. For instance, a propensity-score analysis found no benefi t from prophylactic PCI (using stents in the vast majority of cases) in patients with coronary artery disease in terms of adverse coronary events or death following aortic surgery. 14 In patients who have undergone prior PCI, noncardiac surgery poses special challenges, especially in relation to stents. Restenosis is a particular concern with the use of bare-metal stents, and development of stent thrombosis is a particular risk with the use of drugeluting stents. 15 The use of drug-eluting stents requires intensive antiplatelet therapy for at least 1 year following stent implantation to prevent stent thrombosis. 16 
Time interval to surgery after bare-metal stent placement
The effect of prior PCI with bare-metal stents on outcomes following noncardiac surgery was examined in a recent large retrospective study by Nuttall et al. 17 The incidence of major cardiac events was found to be lowest when noncardiac surgery was performed more than 90 days after PCI with bare-metal stents. Using patients who had a greater than 90-day interval before surgery as the reference group, propensity analysis showed that performing surgery within 30 days of PCI was associated with an odds ratio of 3.6 for major cardiac events. The odds ratio was reduced to 1.6 when surgery was performed 31 to 90 days after PCI. These fi ndings suggest that 30 days may be an ideal minimum time interval, from a risk/benefi t standpoint, between PCI with baremetal stents and noncardiac surgery.
Time interval to surgery after drug-eluting stent placement
A recent retrospective study by Rabbitts et al examined patients who had noncardiac surgery after prior PCI with drug-eluting stents, focusing on the relationship between the timing of the procedures and major cardiac events during hospitalization for the surgery. 18 Although the frequency of major cardiac events was not statistically signifi cantly associated with the time between stent placement and surgery, the frequency was lowest-3.3%-when surgery followed drug-eluting stent placement by more than 365 days (versus rates of 5.7% to 6.4% for various intervals of less than 365 days).
ACC/AHA recommendations
Recommendations on the timing of noncardiac surgery in patients with prior PCI from the ACC/AHA 2007 perioperative guidelines (Figure 1) are consistent with the fi ndings of the above two retrospective studies, 17, 18 although the guideline writers concede that these recommendations are based on expert opinion and lack highquality supportive evidence. 1 Indeed, stent thrombosis has been known to occur during operations performed 18 months or more after drug-eluting stent placement, so vigilance is always in order.
Timing of antiplatelet interruption
Results from a prospectively maintained Dutch registry 19 are consistent with the fi ndings reviewed above: patients who underwent noncardiac surgery less than 30 days after bare-metal stent implantation or less than 6 months after drug-eluting stent implantation (early surgery group) had a signifi cantly elevated rate of major cardiac events compared with patients in whom the interval between stenting and noncardiac surgery was longer (late surgery group). Notably, this report also 
Proposed approach to management of patients with prior PCI
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found that the rate of major cardiac events within the early surgery group was signifi cantly higher in patients whose antiplatelet therapy was discontinued during the preoperative period than in those whose antiplatelet therapy was not stopped. 19 A hypercoagulable state develops within 7 to 10 days after interruption of antiplatelet therapy, at which time the patient is vulnerable to thrombosis. In general, surgery should not proceed during this time without antiplatelet coverage.
From my perspective, giving ketorolac or aspirin the morning of surgery may be benefi cial for patients whose antiplatelet therapy has been stopped 7 to 10 days previously, although no data from randomized trials exist to support this practice. Theoretically, it is reasonable to stop antiplatelet therapy 4 to 5 days before surgery in patients with an increased risk of bleeding without exposing them to the hypercoagulability that would set in if therapy were stopped earlier.
  A FRAMEWORK FOR CARDIAC EVALUATION
The ACC/AHA 2007 perioperative guidelines include an evidence-based algorithm for determining which patients are candidates for cardiac testing as part of preoperative cardiac assessment. 1 As presented in Figure 2 , this stepwise approach takes into account the urgency of the surgery, the presence or absence of active cardiac conditions, the type of surgery and its risk level, and the patient's functional capacity and cardiac risk factors. 1, 20 The following are among the algorithm's key recommendations:
• Patients requiring urgent noncardiac surgery should proceed to the operating room with perioperative surveillance (Class I, Level C).
• Patients with active cardiac conditions who are undergoing nonurgent surgery should be evaluated and treated per ACC/AHA guidelines before proceeding to the operating room is considered (Class I, Level B).
• Patients scheduled for a low-risk procedure can proceed to surgery without testing (Class I, Level B).
• Patients scheduled for intermediate-risk surgery or vascular surgery are to be assessed by functional capacity and clinical risk factors. Proceeding with planned surgery is appropriate in patients with good functional capacity (Class IIa, Level B). In patients with poor or unknown functional capacity undergoing vascular surgery who have three or more clinical risk factors, testing should be considered if the results would change management (Class IIa, Level B).
• Patients with one or more clinical risk factors undergoing intermediate-risk surgery and those with fewer than three clinical risk factors undergoing vascular surgery may proceed to planned surgery with control of heart rate to diminish the stress response perioperatively (Class IIa, Level B), or they may undergo noninvasive testing, but only if the results would change management (Class IIb, Level B).
• Patients undergoing intermediate-risk or vascular surgery who have poor or unknown functional capacity but no clinical risk factors may proceed to surgery without testing (Class I, Level B).
  DISCUSSION
Question from the audience: The POISE study showed a 30% reduction in nonfatal MI with routine perioperative beta-blockade but an overall increase in mortality. Since most MIs occur immediately postoperatively and sepsis occurs a bit later, would you consider continuing beta-blocker therapy for a few days to prevent an MI but then stopping it before sepsis develops? Dr. Fleisher: I've had discussions with sepsis experts about the link between beta-blocker therapy and sepsis and death in POISE, and the belief is that beta-blockers do not cause sepsis. I think that a septic patient on acute high-dose beta-blocker therapy can't respond appropriately because of an inability to increase cardiac output. I believe we should titrate beta-blockers more closely. Information on preoperative dose titration in POISE is not available because of the way the trial was designed. Sepsis developed in only 53 of the 8,351 patients randomized in the study.
I would not start an acute beta-blocker protocol just to get a patient through surgery. I would start a perioperative hemodynamic protocol with the goal of maintaining the patient's heart rate at lower than 80 beats per minute. Because I don't believe that beta-blockers cause sepsis, if I initiated a beta-blocker preoperatively, I would not stop it at 2 days.
Question from the audience: Is there a time period during which a patient with a bare-metal stent could have back surgery or knee replacement surgery while not on aspirin?
Dr. Fleisher: The guidelines say that if a patient is on aspirin, it should be continued indefi nitely. The issue is one of risk versus benefi t. For back surgery, if bleeding is a concern, stopping aspirin for 6 or 7 days after the 30-day period following PCI is not unreasonable, but I would not stop it during the fi rst 30 days following PCI.
Question from the audience: I don't assess for vascular surgery but rather for the Whipple procedure [radical pancreatoduodenectomy], and I use the Revised Cardiac Risk Index to assess the number of risk factors. I believe the Whipple procedure is a high-risk operation, but it appears to be considered an intermediate-risk operation by the ACC/AHA guidelines. Is my approach to risk assessment appropriate?
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Dr. Fleisher: If the rates of morbidity and mortality with the Whipple procedure are low at your institution, you might risk worsening your outcomes by applying someone else's paradigms to your institution. There's a big difference in risk between a surgeon who does a Whipple in 5 hours with 0.5 to 1.0 U of blood loss and a surgeon who does a 12-hour Whipple with 20 U of blood loss, necessitating a stay in the intensive care unit for multiple days. You need to consider the risk associated with your institution and specifi cally with the surgeon.
Question from the audience: Peripheral vascular disease is considered a coronary heart disease risk equivalent, so why is it not one of the criteria in the Revised Cardiac Risk Index? Dr. Fleisher: The criteria are not hard and fast. The index was devised at one institution, Brigham and Women's Hospital, in about 4,000 patients, and it has been used Consider testing if it will change management ‡ * Noninvasive testing may be considered before surgery in specifi c patients with risk factors if it will change management.
† Clinical risk factors include ischemic heart disease, compensated or prior heart failure, diabetes mellitus, renal insuffi ciency, and cerebrovascular disease. ‡ Consider perioperative beta-blockade for populations in which this has been shown to reduce cardiac morbidity/mortality. LOE = level of evidence; MET = metabolic equivalent Proceed with planned surgery with heart rate control ‡ (Class IIa Step 1
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Step Recommended approach to cardiac evaluation and care prior to noncardiac surgery FIGURE 2. Algorithm for preoperative cardiac evaluation and care. 1, 20 Reprinted 
